Skip to main content
Heart logoLink to Heart
. 2001 Apr;85(4):e8. doi: 10.1136/heart.85.4.e8

Serious adverse events experienced by patients with chronic heart failure taking spironolactone

C Berry, J McMurray
PMCID: PMC1729677  PMID: 11250985

Abstract

In patients with chronic heart failure, spironolactone added to conventional treatment may lead to serious and, occasionally, fatal hyperkalaemia. In some cases this seems to happen because spironolactone causes diarrhoea. Four cases involving men with New York Heart Association functional class III heart failure are presented. As these cases revealed, close monitoring of blood chemistry is mandatory after starting spironolactone, and patients should be advised to stop spironolactone immediately if diarrhoea develops.


Keywords: spironolactone; heart failure; hyperkalaemia

Full Text

The Full Text of this article is available as a PDF (64.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. DeFronzo R. A. Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int. 1980 Jan;17(1):118–134. doi: 10.1038/ki.1980.14. [DOI] [PubMed] [Google Scholar]
  2. McMurray J., Matthews D. M. Consequences of fluid loss in patients treated with ACE inhibitors. Postgrad Med J. 1987 May;63(739):385–387. doi: 10.1136/pgmj.63.739.385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Pitt B., Zannad F., Remme W. J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709–717. doi: 10.1056/NEJM199909023411001. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES